---
document_datetime: 2025-12-02 05:16:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/okedi.html
document_name: okedi.html
version: success
processing_time: 0.1041628
conversion_datetime: 2025-12-24 20:08:44.259046
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Okedi

[RSS](/en/individual-human-medicine.xml/67532)

##### Authorised

This medicine is authorised for use in the European Union

risperidone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Okedi](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Okedi is a medicine used to treat schizophrenia in adults. It contains the active substance risperidone and is intended for use in patients in whom medicines containing risperidone have been effective and have not produced unacceptable side effects when given by mouth.

Okedi is a type of medicine called a 'hybrid medicine'. This means that it is similar to a reference medicine containing the same active substance, but it is presented in a different way. While the reference medicine for Okedi, Risperdal tablets, is taken daily by mouth, Okedi is provided as a monthly injection.

Expand section

Collapse section

## How is Okedi used?

Okedi is available as an injection to be given into the muscle of the upper arm or buttocks. It can only be obtained with a prescription and should be given by a healthcare professional. The starting dose is either 75 or 100 mg, depending on the patient's previous dose of risperidone by mouth, and injections are given every 28 days. Patients who are not currently treated with risperidone by mouth should be switched to such treatment for a period before starting Okedi.

For more information about using Okedi, see the package leaflet or contact your doctor or pharmacist.

## How does Okedi work?

Risperidone is a so-called antipsychotic medicine that has been used in the treatment of schizophrenia for several decades. In the brain, risperidone attaches to receptors (targets) on nerve cells. This disrupts signals transmitted between brain cells by 'neurotransmitters', chemicals that allow nerve cells to communicate with each other. Risperidone acts mainly by blocking certain receptors for the neurotransmitters dopamine and 5?hydroxytryptamine (also called serotonin), which are involved in schizophrenia. By blocking these receptors, the medicine helps to normalise the activity of the brain and reduce symptoms of the disease.

The risperidone in Okedi is formulated as a suspension of tiny particles. After injection a small amount of the active substance is immediately available, with the remainder being slowly released over several weeks after injection, helping to prolong the action of the medicine.

## How has Okedi been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Risperdal, and therefore do not all need to be repeated for Okedi.

As for every medicine, the company provided studies on the quality of Okedi. The company also carried out studies that showed that levels of the active substance in the body after Okedi injection were comparable to those produced by the reference medicine taken by mouth, and that Okedi could therefore be expected to have the same effect.

In addition, the company provided results from a main study that looked at the effectiveness of Okedi in 390 patients who were having a flare-up of schizophrenia symptoms. Benefit was measured as the fall in a measurement of schizophrenia severity called the PANSS score. Average PANSS score fell by around 25 in patients given Okedi 75 or 100 mg, compared with a fall of 11 in those given placebo (a dummy treatment). About 30 to 40% in those given Okedi had a fall in PANSS score of at least 30%, compared with about 8% in those given placebo.

## What are the benefits and risks of Okedi?

Because Okedi produces levels of active substance in the body comparable to those seen in the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Okedi authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Okedi has been shown to have comparable quality and to produce comparable levels of active substance to Risperdal.

Prolonged-release formulations offer advantages in patients with schizophrenia who have difficulty in sticking to regular dosing by mouth, but are problematic if severe side effects develop. The Agency's view was that the risk of these could be sufficiently identified by an initial period of giving risperidone by mouth and Okedi can therefore be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Okedi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Okedi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Okedi are continuously monitored. Suspected side effects reported with Okedi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Okedi

Okedi received a marketing authorisation valid throughout the EU on 14 February 2022.

Okedi : EPAR - Medicine Overview

Reference Number: EMA/72969/2022

English (EN) (123.77 KB - PDF)

**First published:** 01/03/2022

[View](/en/documents/overview/okedi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-739)

български (BG) (144.57 KB - PDF)

**First published:**

01/03/2022

[View](/bg/documents/overview/okedi-epar-medicine-overview_bg.pdf)

español (ES) (119.34 KB - PDF)

**First published:**

01/03/2022

[View](/es/documents/overview/okedi-epar-medicine-overview_es.pdf)

čeština (CS) (143.14 KB - PDF)

**First published:**

01/03/2022

[View](/cs/documents/overview/okedi-epar-medicine-overview_cs.pdf)

dansk (DA) (118.51 KB - PDF)

**First published:**

01/03/2022

[View](/da/documents/overview/okedi-epar-medicine-overview_da.pdf)

Deutsch (DE) (122.23 KB - PDF)

**First published:**

01/03/2022

[View](/de/documents/overview/okedi-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.97 KB - PDF)

**First published:**

01/03/2022

[View](/et/documents/overview/okedi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.56 KB - PDF)

**First published:**

01/03/2022

[View](/el/documents/overview/okedi-epar-medicine-overview_el.pdf)

français (FR) (119.68 KB - PDF)

**First published:**

01/03/2022

[View](/fr/documents/overview/okedi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.66 KB - PDF)

**First published:**

01/03/2022

[View](/hr/documents/overview/okedi-epar-medicine-overview_hr.pdf)

italiano (IT) (118.04 KB - PDF)

**First published:**

01/03/2022

[View](/it/documents/overview/okedi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (147.76 KB - PDF)

**First published:**

01/03/2022

[View](/lv/documents/overview/okedi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.84 KB - PDF)

**First published:**

01/03/2022

[View](/lt/documents/overview/okedi-epar-medicine-overview_lt.pdf)

magyar (HU) (138.69 KB - PDF)

**First published:**

01/03/2022

[View](/hu/documents/overview/okedi-epar-medicine-overview_hu.pdf)

Malti (MT) (141.78 KB - PDF)

**First published:**

01/03/2022

[View](/mt/documents/overview/okedi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (119.63 KB - PDF)

**First published:**

01/03/2022

[View](/nl/documents/overview/okedi-epar-medicine-overview_nl.pdf)

polski (PL) (143.83 KB - PDF)

**First published:**

01/03/2022

[View](/pl/documents/overview/okedi-epar-medicine-overview_pl.pdf)

português (PT) (119.55 KB - PDF)

**First published:**

01/03/2022

[View](/pt/documents/overview/okedi-epar-medicine-overview_pt.pdf)

română (RO) (139.21 KB - PDF)

**First published:**

01/03/2022

[View](/ro/documents/overview/okedi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.05 KB - PDF)

**First published:**

01/03/2022

[View](/sk/documents/overview/okedi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (139.18 KB - PDF)

**First published:**

01/03/2022

[View](/sl/documents/overview/okedi-epar-medicine-overview_sl.pdf)

Suomi (FI) (114.86 KB - PDF)

**First published:**

01/03/2022

[View](/fi/documents/overview/okedi-epar-medicine-overview_fi.pdf)

svenska (SV) (116.28 KB - PDF)

**First published:**

01/03/2022

[View](/sv/documents/overview/okedi-epar-medicine-overview_sv.pdf)

Okedi : EPAR - Risk management plan summary

English (EN) (85.07 KB - PDF)

**First published:** 01/03/2022

[View](/en/documents/rmp-summary/okedi-epar-risk-management-plan-summary_en.pdf)

## Product information

Okedi : EPAR - Product Information

English (EN) (1.82 MB - PDF)

**First published:** 01/03/2022

**Last updated:** 14/10/2025

[View](/en/documents/product-information/okedi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-50)

български (BG) (2.27 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/bg/documents/product-information/okedi-epar-product-information_bg.pdf)

español (ES) (2.5 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/es/documents/product-information/okedi-epar-product-information_es.pdf)

čeština (CS) (3.25 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/cs/documents/product-information/okedi-epar-product-information_cs.pdf)

dansk (DA) (3.32 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/da/documents/product-information/okedi-epar-product-information_da.pdf)

Deutsch (DE) (2.77 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/de/documents/product-information/okedi-epar-product-information_de.pdf)

eesti keel (ET) (2.22 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/et/documents/product-information/okedi-epar-product-information_et.pdf)

ελληνικά (EL) (2.32 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/el/documents/product-information/okedi-epar-product-information_el.pdf)

français (FR) (2.57 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/fr/documents/product-information/okedi-epar-product-information_fr.pdf)

hrvatski (HR) (2.45 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/hr/documents/product-information/okedi-epar-product-information_hr.pdf)

íslenska (IS) (2.66 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/is/documents/product-information/okedi-epar-product-information_is.pdf)

italiano (IT) (2.57 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/it/documents/product-information/okedi-epar-product-information_it.pdf)

latviešu valoda (LV) (2.58 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/lv/documents/product-information/okedi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.36 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/lt/documents/product-information/okedi-epar-product-information_lt.pdf)

magyar (HU) (2.26 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/hu/documents/product-information/okedi-epar-product-information_hu.pdf)

Malti (MT) (1.99 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/mt/documents/product-information/okedi-epar-product-information_mt.pdf)

Nederlands (NL) (2.72 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/nl/documents/product-information/okedi-epar-product-information_nl.pdf)

norsk (NO) (2.74 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/no/documents/product-information/okedi-epar-product-information_no.pdf)

polski (PL) (1.6 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/pl/documents/product-information/okedi-epar-product-information_pl.pdf)

português (PT) (2.43 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/pt/documents/product-information/okedi-epar-product-information_pt.pdf)

română (RO) (2.58 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/ro/documents/product-information/okedi-epar-product-information_ro.pdf)

slovenčina (SK) (2.75 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/sk/documents/product-information/okedi-epar-product-information_sk.pdf)

slovenščina (SL) (2.27 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/sl/documents/product-information/okedi-epar-product-information_sl.pdf)

Suomi (FI) (2.67 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/fi/documents/product-information/okedi-epar-product-information_fi.pdf)

svenska (SV) (2.01 MB - PDF)

**First published:**

01/03/2022

**Last updated:**

14/10/2025

[View](/sv/documents/product-information/okedi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000296174 11/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Okedi : EPAR - All authorised presentations

English (EN) (51.11 KB - PDF)

**First published:** 01/03/2022

[View](/en/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-812)

български (BG) (53.81 KB - PDF)

**First published:**

01/03/2022

[View](/bg/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.28 KB - PDF)

**First published:**

01/03/2022

[View](/es/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48.19 KB - PDF)

**First published:**

01/03/2022

[View](/cs/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.53 KB - PDF)

**First published:**

01/03/2022

[View](/da/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (44.55 KB - PDF)

**First published:**

01/03/2022

[View](/de/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (43.86 KB - PDF)

**First published:**

01/03/2022

[View](/et/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (47.88 KB - PDF)

**First published:**

01/03/2022

[View](/el/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_el.pdf)

français (FR) (45.57 KB - PDF)

**First published:**

01/03/2022

[View](/fr/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (46.42 KB - PDF)

**First published:**

01/03/2022

[View](/hr/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.28 KB - PDF)

**First published:**

01/03/2022

[View](/is/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.96 KB - PDF)

**First published:**

01/03/2022

[View](/it/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (47.96 KB - PDF)

**First published:**

01/03/2022

[View](/lv/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (46.63 KB - PDF)

**First published:**

01/03/2022

[View](/lt/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (47.66 KB - PDF)

**First published:**

01/03/2022

[View](/hu/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (59.56 KB - PDF)

**First published:**

01/03/2022

[View](/mt/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.25 KB - PDF)

**First published:**

01/03/2022

[View](/nl/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.63 KB - PDF)

**First published:**

01/03/2022

[View](/no/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_no.pdf)

polski (PL) (49.34 KB - PDF)

**First published:**

01/03/2022

[View](/pl/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.54 KB - PDF)

**First published:**

01/03/2022

[View](/pt/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_pt.pdf)

română (RO) (46.49 KB - PDF)

**First published:**

01/03/2022

[View](/ro/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (49.12 KB - PDF)

**First published:**

01/03/2022

[View](/sk/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (46.47 KB - PDF)

**First published:**

01/03/2022

[View](/sl/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.07 KB - PDF)

**First published:**

01/03/2022

[View](/fi/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.63 KB - PDF)

**First published:**

01/03/2022

[View](/sv/documents/all-authorised-presentations/okedi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Okedi Active substance risperidone International non-proprietary name (INN) or common name risperidone Therapeutic area (MeSH) Schizophrenia Anatomical therapeutic chemical (ATC) code N05AX08

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

## Authorisation details

EMA product number EMEA/H/C/005406 Marketing authorisation holder

Laboratorios Farmacéuticos Rovi, S.A.

Julián Camarillo, 35

Opinion adopted 16/12/2021 Marketing authorisation issued 14/02/2022 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Okedi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (129.03 KB - PDF)

**First published:** 14/10/2025

[View](/en/documents/procedural-steps-after/okedi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Okedi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (120.66 KB - PDF)

**First published:** 01/08/2022

**Last updated:** 14/10/2025

[View](/en/documents/procedural-steps-after/okedi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Okedi : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/CHMP/11233/2022 rev.1

English (EN) (3.94 MB - PDF)

**First published:** 01/03/2022

[View](/en/documents/assessment-report/okedi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Okedi

Adopted

Reference Number: EMA/CHMP/726160/2021

English (EN) (157.11 KB - PDF)

**First published:** 17/12/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-okedi_en.pdf)

#### News on Okedi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021) 17/12/2021

**This page was last updated on** 14/10/2025

## Share this page

[Back to top](#main-content)